Supramolecular cisplatin-vorinostat nanodrug for overcoming drug resistance in cancer synergistic therapy

Journal of Controlled Release

Volumn 266, Issue , 2017, Pages 36-46

  Xu, Shuting ^a   Zhu, Xinyuan ^a   Huang, Wei ^a   Zhou, Yongfeng ^a   Yan, Deyue ^a  

^a SHANGHAI JIAO TONG UNIVERSITY   (China)

Author keywords

Anti drug resistance; Cancer; Cisplatin; Nanodrug; Self delivery; Synergistic therapy

Indexed keywords

CONTROLLED DRUG DELIVERY; DISEASES; DRUG DOSAGE; DRUG INTERACTIONS; SUPRAMOLECULAR CHEMISTRY; TUMORS;

CANCER; CIS-PLATIN; DRUG RESISTANCE; NANODRUG; SELF-DELIVERY; SYNERGISTIC THERAPY;

TARGETED DRUG DELIVERY;

CISPLATIN; VORINOSTAT; ANTINEOPLASTIC AGENT; DRUG CARRIER; GLUTATHIONE; HYDROXAMIC ACID; NANOPARTICLE;

A-549 CELL LINE; ANIMAL EXPERIMENT; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; BLOOD FLOW; CANCER INHIBITION; CANCER RESISTANCE; CANCER TISSUE; CELL PROLIFERATION; CONTROLLED STUDY; CYTOTOXICITY; DRUG DISTRIBUTION; DRUG MIXTURE; DRUG POTENTIATION; DRUG SYNTHESIS; FEMALE; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; MOUSE; NONHUMAN; PRIORITY JOURNAL; RAT; SUPRAMOLECULAR CHEMISTRY; TUMOR GROWTH; TUMOR LOCALIZATION; ANIMAL; BAGG ALBINO MOUSE; CELL SURVIVAL; CHEMISTRY; DRUG EFFECT; DRUG RELEASE; DRUG RESISTANCE; METABOLISM; NEOPLASM; NUDE MOUSE;

A549 CELLS; ANIMALS; ANTINEOPLASTIC AGENTS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CELL SURVIVAL; CISPLATIN; DRUG CARRIERS; DRUG LIBERATION; DRUG RESISTANCE, NEOPLASM; DRUG SYNERGISM; FEMALE; GLUTATHIONE; HUMANS; HYDROXAMIC ACIDS; MICE, INBRED BALB C; MICE, NUDE; NANOPARTICLES; NEOPLASMS;

EID: 85029481162     PISSN: 01683659     EISSN: 18734995     Source Type: Journal    
DOI: 10.1016/j.jconrel.2017.09.007     Document Type: Article

References (41)

1. Siegel, R.L., Miller, K.D., Jemal, A., Cancer statistics, 2016. CA Cancer J. Clin. 66 (2016), 7–30.
2. Olaussen, K.A., Dunant, A., Fouret, P., Brambilla, E., André, F., Haddad, V., Taranchon, E., Filipits, M., Pirker, R., Popper, H.H., Stahel, R., Sabatier, L., Pignon, J.-P., Tursz, T., Le Chevalier, T., Soria, J.-C., DNA repair by ERCC1 in non–small-cell lung cancer and cisplatin-based adjuvant chemotherapy. N. Engl. J. Med. 355 (2006), 983–991.
3. Turner, N.C., Reis-Filho, J.S., Genetic heterogeneity and cancer drug resistance. Lancet Oncol. 13 (2012), e178–e185.
4. Ardizzoni, A., Boni, L., Tiseo, M., Fossella, F.V., Schiller, J.H., Paesmans, M., Radosavljevic, D., Paccagnella, A., Zatloukal, P., Mazzanti, P., Bisset, D., Rosell, R., Cisplatin-versus carboplatin-based chemotherapy in first-line treatment of advanced non–small-cell lung cancer: an individual patient data Meta-analysis. J. Natl. Cancer Inst. 99 (2007), 847–857.
5. Wang, D., Lippard, S.J., Cellular processing of platinum anticancer drugs. Nat. Rev. Drug Discov. 4 (2005), 307–320.
6. Ivanov, A.I., Christodoulou, J., Parkinson, J.A., Barnham, K.J., Tucker, A., Woodrow, J., Sadler, P.J., Cisplatin binding sites on human albumin. J. Biol. Chem. 273 (1998), 14721–14730.
7. Rabik, C.A., Dolan, M.E., Molecular mechanisms of resistance and toxicity associated with platinating agents. Cancer Treat. Rev. 33 (2007), 9–23.
8. Köberle, B., Tomicic, M.T., Usanova, S., Kaina, B., Cisplatin resistance: preclinical findings and clinical implications. Biochim. Biophys. Acta (BBA) – Rev. Cancer 1806 (2010), 172–182.
9. Shen, D.-W., Pouliot, L.M., Hall, M.D., Gottesman, M.M., Cisplatin resistance: a cellular self-defense mechanism resulting from multiple epigenetic and genetic changes. Pharmacol. Rev. 64 (2012), 706–721.
10. Stordal, B., Pavlakis, N., Davey, R., Oxaliplatin for the treatment of cisplatin-resistant cancer: a systematic review. Cancer Treat. Rev. 33 (2007), 347–357.
11. Wang, X., Guo, Z., Targeting and delivery of platinum-based anticancer drugs. Chem. Soc. Rev. 42 (2013), 202–224.
12. Hu, Q., Sun, W., Wang, C., Gu, Z., Recent advances of cocktail chemotherapy by combination drug delivery systems. Adv. Drug Deliv. Rev. 98 (2016), 19–34.
13. Huang, W.-J., Tang, Y.-A., Chen, M.-Y., Wang, Y.-J., Hu, F.-H., Wang, T.-W., Chao, S.-W., Chiu, H.-W., Yeh, Y.-L., Chang, H.-Y., Juan, H.-F., Lin, P., Wang, Y.-C., A histone deacetylase inhibitor YCW1 with antitumor and antimetastasis properties enhances cisplatin activity against non-small cell lung cancer in preclinical studies. Cancer Lett. 346 (2014), 84–93.
14. Diyabalanage, H.V.K., Granda, M.L., Hooker, J.M., Combination therapy: histone deacetylase inhibitors and platinum-based chemotherapeutics for cancer. Cancer Lett. 329 (2013), 1–8.
15. Raveendran, R., Braude, J.P., Wexselblatt, E., Novohradsky, V., Stuchlikova, O., Brabec, V., Gandin, V., Gibson, D., Pt(iv) derivatives of cisplatin and oxaliplatin with phenylbutyrate axial ligands are potent cytotoxic agents that act by several mechanisms of action. Chem. Sci. 7 (2016), 2381–2391.
16. Mann, B.S., Johnson, J.R., Cohen, M.H., Justice, R., Pazdur, R., FDA approval summary: vorinostat for treatment of advanced primary cutaneous T-cell lymphoma. Oncologist 12 (2007), 1247–1252.
17. Shen, J., Huang, C., Jiang, L., Gao, F., Wang, Z., Zhang, Y., Bai, J., Zhou, H., Chen, Q., Enhancement of cisplatin induced apoptosis by suberoylanilide hydroxamic acid in human oral squamous cell carcinoma cell lines. Biochem. Pharmacol. 73 (2007), 1901–1909.
18. Kim, M.S., Blake, M., Baek, J.H., Kohlhagen, G., Pommier, Y., Carrier, F., Inhibition of histone deacetylase increases cytotoxicity to anticancer drugs targeting DNA. Cancer Res., 63, 2003, 7291.
19. Xiong, Y., Zhao, Y., Miao, L., Lin, C.M., Huang, L., Co-delivery of polymeric metformin and cisplatin by self-assembled core-membrane nanoparticles to treat non-small cell lung cancer. J. Control. Release 244 (2016), 63–73 Part A.
20. Brabec, V., Griffith, D.M., Kisova, A., Kostrhunova, H., Zerzankova, L., Marmion, C.J., Kasparkova, J., Valuable insight into the anticancer activity of the platinum-histone deacetylase inhibitor conjugate, cis-[Pt(NH3)2malSAHA–2H]. Mol. Pharm. 9 (2012), 1990–1999.
21. Griffith, D., Morgan, M.P., Marmion, C.J., A novel anti-cancer bifunctional platinum drug candidate with dual DNA binding and histone deacetylase inhibitory activity. Chem. Commun., 2009, 6735–6737.
22. Greenwald, R.B., Choe, Y.H., McGuire, J., Conover, C.D., Effective drug delivery by PEGylated drug conjugates. Adv. Drug Deliv. Rev. 55 (2003), 217–250.
23. Lee, E.S., Na, K., Bae, Y.H., Doxorubicin loaded pH-sensitive polymeric micelles for reversal of resistant MCF-7 tumor. J. Control. Release 103 (2005), 405–418.
24. Yu, D., Peng, P., Dharap, S.S., Wang, Y., Mehlig, M., Chandna, P., Zhao, H., Filpula, D., Yang, K., Borowski, V., Borchard, G., Zhang, Z., Minko, T., Antitumor activity of poly(ethylene glycol)–camptothecin conjugate: the inhibition of tumor growth in vivo. J. Control. Release 110 (2005), 90–102.
25. Huang, P., Wang, D., Su, Y., Huang, W., Zhou, Y., Cui, D., Zhu, X., Yan, D., Combination of small molecule prodrug and nanodrug delivery: amphiphilic drug–drug conjugate for cancer therapy. J. Am. Chem. Soc. 136 (2014), 11748–11756.
26. Cai, Y., Shen, H., Zhan, J., Lin, M., Dai, L., Ren, C., Shi, Y., Liu, J., Gao, J., Yang, Z., Supramolecular “Trojan Horse” for nuclear delivery of dual anticancer drugs. J. Am. Chem. Soc. 139 (2017), 2876–2879.
27. Matsumura, Y., Maeda, H., A new concept for macromolecular therapeutics in cancer chemotherapy: mechanism of tumoritropic accumulation of proteins and the antitumor agent smancs. Cancer Res. 46 (1986), 6387–6392.
28. Shen, D.W., Su, A., Liang, X.J., Pai-Panandiker, A., Gottesman, M.M., Reduced expression of small GTPases and hypermethylation of the folate binding protein gene in cisplatin-resistant cells. Br. J. Cancer 91 (2004), 270–276.
29. Kartalou, M., Essigmann, J.M., Mechanisms of resistance to cisplatin. Mutat. Res. Fundam. Mol. Mech. Mutagen. 478 (2001), 23–43.
30. Jamieson, E.R., Lippard, S.J., Structure, recognition, and processing of cisplatin − DNA adducts. Chem. Rev. 99 (1999), 2467–2498.
31. Ruefli, A.A., Ausserlechner, M.J., Bernhard, D., Sutton, V.R., Tainton, K.M., Kofler, R., Smyth, M.J., Johnstone, R.W., The histone deacetylase inhibitor and chemotherapeutic agent suberoylanilide hydroxamic acid (SAHA) induces a cell-death pathway characterized by cleavage of Bid and production of reactive oxygen species. Proc. Natl. Acad. Sci. 98 (2001), 10833–10838.
32. Rudin, C.M., Yang, Z., Schumaker, L.M., VanderWeele, D.J., Newkirk, K., Egorin, M.J., Zuhowski, E.G., Cullen, K.J., Inhibition of glutathione synthesis reverses Bcl-2-mediated cisplatin resistance. Cancer Res., 63, 2003, 312.
33. Jin, K.L., Park, J.-Y., Noh, E.J., Hoe, K.L., Lee, J.H., Kim, J.-H., Nam, J.-H., The effect of combined treatment with cisplatin and histone deacetylase inhibitors on HeLa cells. J. Gynecol. Oncol. 21 (2010), 262–268.
34. Diyabalanage, H.V., Granda, M.L., Hooker, J.M., Combination therapy: histone deacetylase inhibitors and platinum-based chemotherapeutics for cancer. Cancer Lett. 329 (2013), 1–8.
35. Cole, S.P.C., Deeley, R.G., Transport of glutathione and glutathione conjugates by MRP1. Trends Pharmacol. Sci. 27 (2006), 438–446.
36. Valdez, B.C., Li, Y., Murray, D., Brammer, J.E., Liu, Y., Hosing, C., Nieto, Y., Champlin, R.E., Andersson, B.S., Differential effects of histone deacetylase inhibitors on cellular drug transporters and their implications for using epigenetic modifiers in combination chemotherapy. Oncotarget, 7, 2016, 63829.
37. Yang, X.-Z., Du, X.-J., Liu, Y., Zhu, Y.-H., Liu, Y.-Z., Li, Y.-P., Wang, J., Rational design of polyion complex nanoparticles to overcome cisplatin resistance in cancer therapy. Adv. Mater. 26 (2014), 931–936.
38. Qi, R., Xiao, H., Wu, S., Li, Y., Zhang, Y., Jing, X., Design and delivery of camplatin to overcome cisplatin drug resistance. J. Mater. Chem. B 3 (2015), 176–179.
39. Xue, X., Hall, M.D., Zhang, Q., Wang, P.C., Gottesman, M.M., Liang, X.-J., Nanoscale drug delivery platforms overcome platinum-based resistance in cancer cells due to abnormal membrane protein trafficking. ACS Nano 7 (2013), 10452–10464.
40. Thornberry, N.A., Lazebnik, Y., Caspases: enemies within. Science, 281, 1998, 1312.
41. Barreto, J.A., O'Malley, W., Kubeil, M., Graham, B., Stephan, H., Spiccia, L., Nanomaterials: applications in cancer imaging and therapy. Adv. Mater. 23 (2011), H18–H40.